Abstract

Triple- negative breast cancer (TNBC) incidence rate has regularly risen over the last decades and is expected to increase in the future. Finding novel treatment options with minimum or no toxicity is of great importance in treating or preventing TNBC. Flavonoids are new attractive molecules that might fulfill this promising therapeutic option. Flavonoids have shown many biological activities, including antioxidant, anti-inflammatory, and anticancer effects. In addition to their anticancer effects by arresting the cell cycle, inducing apoptosis, and suppressing cancer cell proliferation, flavonoids can modulate non-coding microRNAs (miRNAs) function. Several preclinical and epidemiological studies indicate the possible therapeutic potential of these compounds. Flavonoids display a unique ability to change miRNAs’ levels via different mechanisms, either by suppressing oncogenic miRNAs or activating oncosuppressor miRNAs or affecting transcriptional, epigenetic miRNA processing in TNBC. Flavonoids are not only involved in the regulation of miRNA-mediated cancer initiation, growth, proliferation, differentiation, invasion, metastasis, and epithelial-to-mesenchymal transition (EMT), but also control miRNAs-mediated biological processes that significantly impact TNBC, such as cell cycle, immune system, mitochondrial dysregulation, modulating signaling pathways, inflammation, and angiogenesis. In this review, we highlighted the role of miRNAs in TNBC cancer progression and the effect of flavonoids on miRNA regulation, emphasizing their anticipated role in the prevention and treatment of TNBC.

Highlights

  • Breast cancer (BC) is the major and most common repeatedly diagnosed cancer in women, which accounts for 30% of new female cancer cases [1], and the second cause of death in women worldwide [2]

  • This review focuses on the anticancer properties of flavonoids in triple- negative breast cancer (TNBC) through miRNA regulation, utilizing compounds that target various pathways involved in cancer initiation, growth, proliferation, differentiation, survival, migration, invasiveness metastasis, and epithelial-to-mesenchymal transition (EMT)

  • This study suggests that the mir-655/rxx1 and mir-136/RASAL2/MET axis acts as a suppressor of TNBC metastasis [114,183]

Read more

Summary

Introduction

Breast cancer (BC) is the major and most common repeatedly diagnosed cancer in women, which accounts for 30% of new female cancer cases [1], and the second cause of death in women worldwide [2]. Chemoresistance is a challenge that accounts for a significant share of drug failures [18], chemotherapy remains the primary cancer treatment approach It is the only agent approved by the Food and Drug Administration (FDA) in treating nonmetastatic TNBC [19]. Chemoresistance is still a challenge in preventing and treating TNBC, and finding the best options is needed to manage the disease by developing drugs that combat the resistance gene or any target molecules of TNBC, miRNAs. This review focuses on the anticancer properties of flavonoids in TNBC through miRNA regulation, utilizing compounds that target various pathways involved in cancer initiation, growth, proliferation, differentiation, survival, migration, invasiveness metastasis, and epithelial-to-mesenchymal transition (EMT). The miRNA mechanism of action on cancer proliferation, cell cycle, immune system, mitochondrial dysregulation, modulating signaling pathways, inflammation, angiogenesis, invasion and metastasis, and apoptosis will be examined

The Microenvironment of TNBC
Epigenetic Modification and TNBC
MicroRNA Biogenesis and Function
Types of miRNA in TNBC
Oncogenic miRNAs
Tumor Suppressor miRNAs
Flavonoids
Dietary Sources of Flavonoids
Flavonoids in the Prevention and Therapy of TNBC
10.1. Mitochondrial Regulation
10.2. Induction of Apoptosis
10.3. Induction of Cell-Cycle Arrest
10.4. Induction of Autophagy
10.6. Enhancement of Immune Responses
10.7. Promotion of Differentiation
10.8. Inhibition of Proliferation
10.9. Inhibition of Oxidative and Nitrosative Stress
10.10. Reduction of Angiogenesis
10.11. Modulation of Signaling Transduction
10.11.1. PKC Pathway
10.11.5. NF-Kβ Signaling Pathway
10.11.8. SMAD Signaling Pathway
Findings
11. Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.